CVR Medical Corp.

CVR Medical Corp.

CRRVF
CVR Medical Corp.US flagOther OTC
0.00
USD
- -
- -
1,072.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
-0.03
-0.02
-0.01
-0.01
-0.01
-0.08
-0.11
-0.1
-0.05
- -
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
-0.01
-0.06
- -
- -
- -
-0.03
-0.07
-0.06
-0.02
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.29
-0.31
-1.52
-0.93
-0.39
-0.37
-0.31
-0.02
-0.01
-0.03
-0.05
-0.05
-0.07
-0.07
Tangible Book Value per Share
-0.02
-0.02
-0.11
- -
-0.01
-0.01
-0.01
- -
0.01
-0.01
-0.03
-0.04
-0.04
-0.05
Basic Weighted Avg Shares
31
31
6
11
23
23
23
29
58
74
100
101
101
106
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
-2
-7
-7
-5
- -
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-1
-1
- -
- -
- -
- -
- -
- -
-1
-3
-3
-4
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-1
-1
- -
- -
- -
- -
1
2
- -
-2
-3
-4
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
107
107
Market Capitalization
1
- -
- -

Working Capital

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
5
Payables & Accruals
4
4
4
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-109.88%
-217.82%
65.88%
Free Cash Flow
237.12%
31.13%
-51.01%
Net Income, GAAP
271.31%
205.4%
948.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
-0.02
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Darren Day
Full Time Employees
3
Sector
Healthcare
Industry
Medical - Devices
Address
221 West Esplanade North Vancouver BC Canada V7M 3J3
IPO Date
Nov 2, 2016
Website
cvrmed.com
Business
CVR Medical Corp. CVR Medical Corp. (CRRVF), a medical technology company incorporated in 1980 and headquartered in North Vancouver, British Columbia, Canada, develops and commercializes subsonic, infrasonic, and low frequency sound wave analysis technology for healthcare applications; its primary product is the patented Carotid Stenotic Scan (CSS) device, a non-invasive diagnostic tool that detects and measures carotid arterial stenosis to identify patients at risk for ischemic stroke, complementing technologies such as Duplex Doppler ultrasound, magnetic resonance angiography, and computed tomography angiography; the CSS targets patients, payers, and healthcare providers, including primary care physicians, with operations focused on North America. The company offers the CSS as a quick, cost-effective screening solution performed in minutes without radiation, dyes, or certified technicians. In recent developments, CVR Medical executed an amended restructuring agreement in April 2021 to acquire all intellectual property and operational control of the CSS from CVR Global, Inc., including exclusive rights to future innovations and applications beyond carotid artery assessment, subject to shareholder and TSX Venture Exchange approval; this strategic shift eliminated prior dependencies, enabling independent pursuit of clinical trials, FDA submissions, and commercialization while securing a pipeline for product enhancements; earlier, in January 2022, the company announced a capital raise to support these advancements.

Company News

APIChatGPT
  • P3 Health Partners (NASDAQ:PIII) & CVR Medical (OTCMKTS:CRRVF) Head to Head Contrast